• 1
    Spencer CM, McTavish D. Budesonide – A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 85472.
  • 2
    Brattsand R. Overview of newer glucocorticosteroid preparations for IBD. Can J Gastroenterol 1990; 4: 40714.
  • 3
    Hanauer SB, Stathopoulos G. Risk–benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991; 6: 192219.
  • 4
    Edsbäcker S. Budesonide capsules: scientific basis. Drugs Today 2000; 36: 923.
  • 5
    Edsbäcker S, Larsson P, Wollmer P. Gut delivery of budesonide, a topically active corticosteroid, from plain and controlled release capsules. Eur J Gastroenterol Hepatol 2002; 14: 135762 .
  • 6
    Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 20914.
  • 7
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 83641.
  • 8
    Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 8425.
  • 9
    Thomsen OØ, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide–Mesalamine Study Group. N Engl J Med 1998; 339: 3704.
  • 10
    Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002; 122: 205.
  • 11
    Tromm A, Griga T, Mollmann HW, May B, Muller KM, Fisseler-Eckhoff A. Budesonide for the treatment of collagenous colitis: first results of a pilot trial. Am J Gastroenterol 1999; 94: 18715.
    Direct Link:
  • 12
    Clissold SP, Campoli-Richards DM. Omeprazole, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger–Ellison syndrome. Drugs 1986; 32: 1547.
  • 13
    Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283: 43442.
  • 14
    Jönsson G, Åstrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995; 23: 13742.
  • 15
    Lindberg C, Blomqvist A, Paulson J. Determination of (22R,S) budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom 1992; 21: 52533.
  • 16
    Belaiche J, Louis E. Corticosteroid treatment in active Crohn's disease. Acta Gastroenterol Belg 1998; 61: 1537.
  • 17
    Hussain F, Trudgill N, Riley S. Mesalazine release from a pH-dependent formulation: effect of concurrent omeprazole administration. Gastroenterology 1995; 108: A840(Abstract).
  • 18
    Petersen KU. Omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995; 9: 19.
  • 19
    Press AG, Hauptmann IA, Hauptmann L, et al. pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12: 6738.
  • 20
    Olbe L, Cederberg C, Lind T, Olausson M. Effect of omeprazole on gastric acid secretion and plasma gastrin. J Gastroenterol Hepatol 1989; 4(Suppl. 2): 1925.
  • 21
    Olbe L, Lind T, Cederberg C, Ekenved G. Effect of omeprazole on gastric acid secretion in man. Scand J Gastroenterol Suppl 1986; 118: 1057.
  • 22
    Prichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 649.
  • 23
    Naesdal J, Bodemar G, Walan A. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 1984; 19: 91622.
  • 24
    Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 95764.
  • 25
    Howden CW, Jones DB, Burget DW, Hunt RH. Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer. Gut 1986; 27: 105861.
  • 26
    Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993; 82: 85772.
  • 27
    Gan KH, Geus WP, Lamers CB, Heijerman HG. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects. Dig Dis Sci 1997; 42: 23049.
  • 28
    Hemery P, Galmiche JP, Roze C, et al. Low dose omeprazole: effects on gastric acid secretion in normal man. Gastroenterol Clin Biol 1987; 11: 14853.
  • 29
    Naesdal J, Bankel M, Bodemar G, Gotthard R, Lundquist G, Walan A. The effect of 20 mg omeprazole daily on serum gastrin, 24-h intragastric acidity, and bile acid concentration in duodenal ulcer patients. Scand J Gastroenterol 1987; 22: 512.
  • 30
    Nakamura T, Arai Y, Tando Y, et al. Effect of omeprazole on changes in gastric and upper small intestine pH levels in patients with chronic pancreatitis. Clin Ther 1995; 17: 44859.
  • 31
    Edsbäcker S, Wollmer P, Bengtsson B, Lundin P, Nilsson M. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 2002 in press .
  • 32
    Abrahao LJ Jr, Abrahao LJ, Vargas C, Chagas V, Fogaca H. Gastroduodenal Crohn's disease — report of 4 cases and review of the literature. Arq Gastroenterol 2001; 38: 5762 (in Portuguese).